Pharmacy
Become a Member Today!
Email
Password
Remember me
Forgot your Password?

Invite Code?


Article ID

Home
General Pharmacy
Messages
Conferences
Jobs
Newsletters
My Library
Topics in
Pharmacy
        Adverse Drug Reactions
        Antimicrobials
        Basic Science
        Cardiac/Hypertension
        Chemotherapy/Oncology
        Complementary Medicine
        Dosing
        Drug Approvals
        Drug Interactions
        Drug Resistance
        Drug Trials
        Drug/Product Alerts
        Economics of Medicine
        Major Studies
        Neuro/Psych pharmacology
        Other Drugs
        Over The Counter (OTC)
        Pain Management
        Patient Counseling
        Pharmacoeconomics
        Pharmacokinetics
        Pharmacy Management
        Popular Press
        Stomach/GI
 
Help
Resource Center
RSS News Feeds
Send Newsletter
to a Friend
 
Sponsor

Messages

The Best of 2009
D Scott Cunningham MD, PhD, MDLinx Oncology
  See all

Articles: Chemotherapy/Oncology



Latest (5) Month's Top Read Top 50 of Year  
Receive free subspecialty "5-minute updates" via email

Prior Articles


Bioequivalence of two film-coated tablets of imatinib mesylate 400 mg: A randomized, open-label, single-dose, fasting, two-period, two-sequence crossover comparison in healthy male South American volunteers
Clinical Therapeutics, 12/01/09
Sponsor
Phase I Study of Flavopiridol with Oxaliplatin and Fluorouracil/Leucovorin in Advanced Solid Tumors
Clinical Cancer Research, 12/01/09
Phase I dose-escalation study of brostallicin, a minor groove binder, in combination with cisplatin in patients with advanced solid tumors
Cancer Chemotherapy and Pharmacology, 12/01/09
Seliciclib in malignancies
Expert Opinion on Investigational Drugs, 11/30/09
Antiangiogenic Drugs in Oncology: A Focus on Drug Safety and the Elderly - A Mini-Review
Gerontology, 11/30/09    Free full text    Revew Article
Valproic acid restores ERalpha and antiestrogen sensitivity to ERalpha-negative breast cancer cells
Molecular and Cellular Endocrinology, 11/25/09    Free full text
Exclusive Author Commentary
N2 Disease in Patients With Head and Neck Squamous Cell Cancer Treated With Chemoradiotherapy
Archives of Otolaryngology, 11/25/09
Salvage treatment with upfront melphalan 100 mg/m2 and consolidation with novel drugs for fulminant progression of multiple myeloma
Annals of Hematology, 11/24/09
Tumor-Associated Lymphocytes As an Independent Predictor of Response to Neoadjuvant Chemotherapy in Breast Cancer
Journal of Clinical Oncology, 11/24/09
The rationale for mTOR inhibition in epithelial ovarian cancer
Expert Opinion on Investigational Drugs, 11/24/09
Ascorbic Acid Potentiation of Arsenic Trioxide Anticancer Activity Against Acute Promyelocytic Leukemia
Archives of Drug Information, 11/24/09
Exclusive Author Commentary
Clinical efficacy of a bortezomib, cyclophosphamide, thalidomide, and dexamethasone (Vel-CTD) regimen in patients with relapsed or refractory multiple myeloma: a phase II study
Annals of Hematology, 11/24/09
Good clinical endpoints with denosumab in osteoporosis and cancer
Expert Opinion in Pharmacotherapy, 11/23/09
Cytoreductive Surgery and Hyperthermic Intraperitoneal Chemotherapy for Malignant Peritoneal Mesothelioma: Multi-Institutional Experience
Journal of Clinical Oncology, 11/23/09
VNCOP-B plus rituximab therapy in elderly patients with aggressive B-cell non-Hodgkin lymphoma: A multicenter experience
Archives of Gerontology and Geriatrics, 11/23/09
Phase 2 study of two sequential three-drug combinations containing bortezomib, cyclophosphamide and dexamethasone, followed by bortezomib, thalidomide and dexamethasone as frontline therapy for multiple myeloma
British Journal of Haematology, 11/20/09
Metronomic chemotherapy with daily, oral etoposide plus bevacizumab for recurrent malignant glioma: a phase II study
British Journal of Cancer, 11/20/09
Multicenter, Phase I, Dose-Escalation Trial of Lenalidomide Plus Bortezomib for Relapsed and Relapsed/Refractory Multiple Myeloma
Journal of Clinical Oncology, 11/20/09
A quality-adjusted survival analysis (Q-TWiST) of rituximab plus CVP vs CVP alone in first-line treatment of advanced follicular non-Hodgkin's lymphoma
British Journal of Cancer, 11/20/09
Loss of HER2 Amplification Following Trastuzumab-Based Neoadjuvant Systemic Therapy and Survival Outcomes
Clinical Cancer Research, 11/20/09

Receive free subspecialty "5-minute updates" via email
Indexed Journals: Expert Opinion in Pharmacotherapy, Formulary, U.S.Pharmacist more...
250 Available Pages
First    Prev    4      5      6      7      8      9      10      11      12      13      Next      Last
Sponsor

Read a Different Specialty

Allergy/Immunology
Anesthesiology
Cardiology
Dermatology
Drugs
Emergency Medicine
Endocrinology
ENT
Family Medicine
Gastroenterology
Hematology-Oncology
Infectious Disease
Internal Medicine
Nephrology
Neurology
OB/Gyn
Ophthalmology
Orthopedics
Pain
Pediatrics
Practice Management
Psychiatry
Pulmonology
Radiology
Rheumatology
Surgery
Urology

Pharmacy Articles Profession Index

Dentist
Hospital Administrator
Nurse
    Medical Students
Nurse Practitioner
Pharma/Drug Marketer
    Pharmacist
Physician Assistants
Article Search
Keyword:
Search:
Published within:
Sort By:
Date Relevance
    
Sponsor
Sponsor
About MDLinx  |  Contact  |  Advertise with MDLinx  |  Site Map  |  Privacy Policy  |  Terms of Use  |  Sign Up For Newsletters  |  Recommend this Site

English |  Español |  Français |  Deutsch |  中文 |  Руccкий |  Norsk |  Nederlands |  Português |  Italiano

©1999-2009 MDLinx, Inc.